GNRH1 and prostate carcinoma: Different from previous studies showing a higher incidence of VTEs in ADT users who were older or at advanced cancer stages, using a multivariable Cox regression to adjust comorbidities, we found a persistently increasing risk of VTEs in overall prostate cancer patients who received GnRH therapies compared with non-users.